Background: Antibody responses to the inactivated seasonal influenza vaccine in patients with atopic dermatitis (AD) have not been carefully characterized. Objective: The primary objective of this study was to compare antibody responses to intradermal vaccination in participants with moderate/severe AD with those in nonatopic participants. Secondary objectives were to evaluate the effect of route of administration, Staphylococcus aureus skin colonization, and disease severity on vaccine response. Methods: This was an open-label study conducted in the 2012-2013 influenza season at 5 US clinical sites. A total of 360 participants with moderate/severe AD or nonatopic subjects were assessed for eligibility, 347 of whom received intradermal or intramuscular vaccination per label and were followed for 28 days after vaccination. The primary outcome was the difference in the proportion of participants achieving seroprotection (hemagglutination-inhibition antibody titer > _1:40 on day 28 after vaccination). Results: Seroprotection rates for influenza B, H1N1, and H3N2 were not different (1) between participants with AD and nonatopic participants receiving intradermal vaccination and (2) between AD participants receiving intradermal and intramuscular vaccination. After intradermal, but not intramuscular, vaccination, participants with AD with S aureus colonization experienced (1) lower seroprotection and seroconversion rates and lower hemagglutination-inhibition antibody titer geometric mean fold
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AD: Atopic dermatitis ADRN: Atopic Dermatitis Research Network GMFI: Geometric mean fold increase GMR: Geometric mean ratio HAI: Hemagglutination-inhibition NJH: National Jewish Health OR: Odds ratio SASC: Staphylococcus aureus skin colonization SEB: Staphylococcal enterotoxin B TSST-1: Toxic shock staph glococol 1 antibody responses to intradermal administration of antigens in patients with AD is unknown, but more than 6 million doses of intradermal seasonal influenza vaccine (personal communication, Dr M. Decker, Sanofi Pasteur) have been administered since it was licensed in the United States in 2011. 10 In the current study the primary analysis compared the antibody responses to intradermal vaccination against influenza strains B, H1N1, and H3N2 in patients with AD compared with those in nonatopic participants. As secondary analyses, we also compared the antibody responses of participants with moderate/ severe AD receiving intradermal versus intramuscular vaccination, antibody responses in participants with AD with and without Staphylococcus aureus skin colonization (SASC), sex, and race.
METHODS
Participants aged 18 to 64 years received open-label vaccination at 5 centers (National Jewish Health [NJH] , University of Rochester, Oregon Health & Science University, Boston Children's Hospital, and Northwestern University) on approval from their institutional review boards. Participants with AD had active moderate/severe skin lesions per the Rajka-Langeland Severity Score. 11 Nonatopic participants had no personal or first-degree family history of AD, asthma, allergic rhinitis, or food allergy. See the Methods section and Table E1 in this article's Online Repository at www.jacionline. org for inclusion/exclusion criteria and classification method of race and ethnicity.
Participants with moderate/severe AD (hereafter referred to as AD) were randomized 1:1 to receive intradermal or intramuscular administration of the 2012-2013 seasonal influenza vaccine. 12 At NJH, nonatopic participants were randomized 3:2 to intradermal or intramuscular vaccination until 23 participants received intramuscular vaccination. Thereafter, the remaining nonatopic participants at NJH received intradermal vaccination. All nonatopic participants at the remaining centers received intradermal vaccination. The 23 nonatopic participants receiving intramuscular vaccination served as a reference group for exploratory analyses (Fig 1) . Stratified block randomization was used to balance sex and AD severity between vaccination routes by clinical site.
Hemagglutination-inhibition (HAI) antibody titers and influenza B-specific IgG 1 , IgG 2 , IgG 3 , and IgA by means of ELISA were measured before vaccination and 28 6 7 days after vaccination. IgE and IgG antibodies specific for toxic shock staph glococol 1 (TSST-1) and staphylococcal enterotoxin B (SEB), total IgE levels, and complete blood counts were measured before vaccination. Prior measurements of total IgE levels and complete blood counts obtained within 30 days of vaccination were used, if available.
S aureus cultures of skin swabs had been obtained previously in nonatopic participants and participants with AD as part of the ADRN Registry. In participants with AD, skin swabs were collected from the participant's most severe AD lesion and also from adjacent nonlesional skin. Methodologies of S aureus culture and laboratory assays are presented in the Methods section in this article's Online Repository. Sensitivity analyses involving SASC were also performed for 2 subgroups: (1) including only participants who had an S aureus culture within 30 days of the vaccination date or (2) including only participants with moderate disease.
For each of the 3 influenza strains, the primary outcome was the proportion of participants achieving seroprotection (HAI antibody titer > _ 1:40 on day 28 after vaccination). Secondary outcomes included the geometric mean fold increase (GMFI) in HAI antibody titers from baseline to day 28 after vaccination and the proportion of participants experiencing seroconversion (> _4-fold increase in baseline HAI antibody titers on day 28 after vaccination). Participants with baseline HAI titers of 1:40 or greater for a particular strain were excluded from the analyses for that particular strain, and counts of those not seroprotected at baseline per strain are included in Fig 1. Demographics and baseline characteristics were compared by using the Fisher exact test for categorical measures and the Wilcoxon 2-sample test for continuous measures. Binary rates are presented as proportions and exact 95% CIs, and comparisons are summarized by using odds ratios (ORs) and the Fisher exact test. Continuous variables were summarized with unadjusted geometric means and 95% CIs. Robust regression models using M-estimation were used to analyze continuous outcomes of log 2 HAI titer fold increase and log 10 influenza B-specific IgG 1 , IgG 2 , IgG 3 , and IgA levels. Geometric mean ratios (GMRs) were defined as the ratio of geometric means of one group to the other. Multiple imputation methodology was used for influenza B-specific IgG 1 , IgG 2 , IgG 3 , and IgA levels outside the limits of quantification. Baseline log 10 IgE and IgG antibodies specific for TSST-1 and SEB were analyzed by using left-censored Tobit regression models. All continuous models adjust for age and sex. The individual effects of SASC and disease severity were analyzed by using an R n 2 test 13 from a similar robust regression model, as described above, that included both SASC and disease severity as covariates.
Sample size calculations were based on H3N2 data from our previous ADRN Influenza Vaccine Pilot Study (NCT01518478) 14 with the intradermal 2011-2012 seasonal influenza vaccine, 15 in which 57% and 85% of participants with AD and nonatopic participants, respectively, achieved seroprotection after vaccination. Because no adjustments were made for multiple comparisons among groups or endpoints, all P values reported are descriptive/hypothesis generating except for the (inferential) P value testing H3N2 seroprotection of participants with AD vs nonatopic participants among those given intradermal vaccination.
By using the Fisher exact test and assuming a 2-sided significance level of .05, a sample size of at least 62 nonatopic participants and 62 participants with AD who were not seroprotected at baseline was necessary to detect a 28% difference in seroprotection rates between participants with AD and nonatopic participants receiving intradermal vaccination with at least 90% power. For secondary objective analyses, we similarly chose a sample size of at least 62 participants with AD without seroprotection at baseline to receive intramuscular vaccination.
RESULTS

Demographics and baseline characteristics
Of 360 candidates screened, 347 were enrolled and vaccinated, and 336 were evaluable in the per-protocol analysis (participants with AD receiving intradermal vaccine, 100; participants with AD receiving intramuscular vaccine, 102; nonatopic participants receiving intradermal vaccine, 111; and nonatopic participants receiving intramuscular vaccine, 23; Fig 1) . A total of 136 (43%) of the 313 participants in the 3 main study groups (participants with AD receiving intradermal vaccine, participants with AD receiving intramuscular vaccine, and nonatopic participants receiving intradermal vaccine) were enrolled and vaccinated at NJH. The proportions of the 3 main study groups enrolled at each site were similar across all sites, except Boston Children's Hospital, where nonatopic participants given intradermal vaccination comprised 65% of its enrollment. Among participants receiving intradermal vaccination, the age of the nonatopic group was higher than that of the AD group (Table I ). The AD group given intradermal vaccination was not different in sex, race, and ethnicity to either the AD group given intramuscular or the nonatopic group given intradermal vaccination. Among recipients of intradermal vaccination, the nonatopic participant group had lower total IgE levels, eosinophil counts, and proportions of SASC than the AD group. These 3 characteristics were similar between both participants with AD receiving intradermal and those receiving intramuscular vaccination.
Baseline severity measures of AD, such as the Eczema Area and Severity Index and the Rajka-Langeland Severity Score, were similar in participants given intradermal and intramuscular vaccination.
Baseline seroprotection rates were similar between the AD and nonatopic groups for each influenza strain; however, baseline seroprotection rates were low for influenza B compared with H1N1 or H3N2 (see Fig E1 in Comparative antibody responses of nonatopic participants and participants with AD after intradermal vaccination There were no differences in seroprotection, seroconversion, or HAI titer GMFI after intradermal vaccination for either influenza B, H1N1, or H3N2 between the nonatopic participants and participants with AD overall (Table II) .
Comparative antibody responses of participants with AD after intradermal or intramuscular vaccination Seroprotection and seroconversion rates and HAI titer GMFIs at day 28 were similar in participants with AD who received intradermal or intramuscular vaccination for each of the 3 strains (Table II) .
Methotrexate (not allowed during the study) The per protocol population includes participants who 1) received a full dose of vaccine, 2) provided serum samples at baseline and day 28, 3) met eligibility criteria, 4) received no prohibited medications, and 5) had no major protocol deviations. Comparative antibody responses of nonatopic participants after intradermal and intramuscular vaccination
As an exploratory analysis, the seroprotection rates of nonatopic participants were similar between those given intradermal vaccination and those given intramuscular vaccination (Table II) .
Effect of S aureus skin colonization on antibody responses to vaccination
Results of S aureus cultures of skin swabs were available in 334 (99%) of 336 participants; cultures were collected up to 477 days before vaccination (mean, 143 days) in 330 (99%) of 334 participants and after vaccination (mean, 37 days) in 4 (1%) of 334 participants. Cultures for 120 (36%) participants were collected within 30 days of vaccination, with cultures for 70 participants collected the same day as vaccination. Overall, 42% of participants with AD were colonized (Table I) . Among all participants with AD who were not seroprotected at baseline separately for influenza B, H1N1, and H3N2, the rates of SASC were 41%, 44%, and 41%, respectively. Participants with AD and SASC were divided evenly between intradermal and intramuscular vaccines.
Baseline TSST-1-specific and SEB-specific IgE and IgG antibodies were higher in participants with AD with SASC compared with participants with AD without SASC (see Fig E2 in this article's Online Repository at www.jacionline.org). Also, participants with AD without SASC had higher baseline TSST-1 and SEB antibody levels than nonatopic participants without SASC.
Comparative antibody responses to intradermal vaccination
The rate of seroprotection to influenza B in participants with AD with SASC was lower than in participants with AD without SASC (11% vs 47%; OR, 0.14; 95% CI, 0.03-0.49; P < .001; Fig 2) . The difference in the rate of seroprotection to influenza B persisted when including only participants with moderate AD (6% vs 51%; OR, 0.06; 95% CI, 0.00-0.50; P 5 .002) or when including only participants with S aureus cultures of skin swabs collected within 30 days of vaccination (0% vs 57%; OR, 0.00; 95% CI, 0.00-0.40; P 5 .004).
Additionally, there was a trend among participants with AD toward a lower H1N1 strain seroprotection rate in those with SASC compared with those without (74% vs 91%; OR, 0.27; 95% CI, 0.04-1.37; P 5 .09).
Among participants with AD, the rate of seroconversion to influenza B and the rate of seroconversion to H1N1 in participants with SASC were also lower than those without SASC (19% vs 52%; OR, 0.23; 95% CI, 0.07-0.64; P 5 .002 and 74% vs 94%; OR, 0.17; 95% CI, 0.02-1.06; P 5 .03, respectively; Fig 2) , which persisted for influenza B when including only participants with moderate AD (25% vs 55%; OR, 0.27; 95% CI, 0.06-1.08; P 5 .05) or when including only participants with skin swabs collected within 30 days of vaccination (11% vs 65%; OR, 0.07; 95% CI, 0.00-0.70; P 5 .02).
Participants with AD and SASC had lower HAI titer GMFIs against influenza B compared with participants with AD without SASC (GMR, 0.50; 95% CI, 0.34-0.74; P <.001; see Fig participants with skin swabs collected within 30 days of vaccination (GMR, 0.39; 95% CI, 0.17-0.88; P 5 .02). Although the HAI titer GMFI against influenza B was influenced by the presence of SASC, it was not influenced by the level of AD severity among intradermal vaccinees. When considering both SASC status and AD severity as covariates in a robust regression model including intradermally vaccinated participants with AD, there were no pairwise differences in HAI titer GMFIs against influenza B between severity levels and only marginal evidence of an overall effect of severity (P 5 .07). However, there was evidence of an overall effect of SASC status on HAI titer GMFIs against influenza B (P 5 .01).
In post hoc analyses, among participants without SASC receiving intradermal vaccination, the seroprotection rates were lower in nonatopic participants than in participants with AD for influenza B (23% vs 47%; OR, 0.34; 95% CI, 0.16-0.72; P 5 .003), and the seroconversion rate for the B strain was also lower in nonatopic participants than in participants with AD (31% vs 52%; OR, 0.41; 95% CI, 0.20-0.85; P 5 .01; Fig 2) .
Comparative antibody responses to intramuscular vaccination
Among participants with AD receiving intramuscular vaccination, SASC status did not affect either the seroprotection rate or the seroconversion rate to any of the 3 strains (Fig 2) . There was a trend, among participants with AD vaccinated intramuscularly, toward a lower HAI titer GMFI against influenza H3N2 in participants with SASC than in participants without SASC (GMR, 0.49; 95% CI, 0.23-1.08; P 5 .08; see Fig E3) .
Comparison of antibody responses between intradermal and intramuscular vaccination in participants with AD and SASC
In a post hoc analysis the proportion of participants with AD with SASC achieving seroprotection to influenza B was lower among those receiving intradermal vaccination than among those receiving intramuscular vaccination (11% vs 39%; OR, 0.20; 95% CI, 0.04-0.72; P 5 .008; Fig 2) . There were similar trends in seroconversion to influenza B (19% vs 41%; OR, 0.34; 95% CI, 0.10-1.06; P 5 .05) and in seroprotection to influenza H1N1 (74% vs 96%; OR, 0.12; 95% CI, 0.00-1.14; P 5 .05; Fig 2) . Vaccination route did not influence immune responses to influenza H3N2 among participants with AD with SASC.
Intradermal vaccination resulted in a lower HAI titer GMFI to the B strain than intramuscular vaccination in participants with AD with SASC (GMR, 0.64; 95% CI, 0.45-0.90; P 5 .01; see Fig E3) . 
Comparison of antibody responses between intradermal and intramuscular vaccination in participants with AD and without SASC
In a post hoc analysis there were no differences between responses to intradermal and intramuscular vaccinations among participants with AD without SASC (Fig 2 and see Fig E3) . 
Effect of S aureus
Comparison of antibody response by sex and race
There were no differences in seroconversion, seroprotection, or HAI titer GMFIs to any vaccine strain between male and female participants or between white and black or African American participants within the groups of participants with AD or nonatopic participants, regardless of vaccination route (data not shown).
Safety summary
A total of 4 adverse events, 2 nonserious and 2 serious and requiring hospitalization, were reported among 3 subjects. All adverse events were grade 3, resolved without sequelae, and deemed not related to the vaccination. One participant with AD receiving intramuscular vaccination experienced simultaneous vomiting and diarrhea 6 days after vaccination, 1 participant with AD receiving intradermal vaccination was hospitalized for an asthma exacerbation 6 days after vaccination, and 1 nonatopic participant receiving intradermal vaccination was hospitalized for a skin infection.
DISCUSSION
The current study is the first immunologic examination of intradermal vaccination against influenza in patients with AD. Seroprotection and seroconversion rates were not different overall between participants with AD and nonatopic control subjects receiving intradermal vaccination for any of the 3 influenza strains (B, H1N1, and H3N2). In contrast, after intradermal vaccination in participants with AD, compared with those without SASC, participants with SASC experienced (1) lower seroprotection and seroconversion rates and lower HAI titer GMFIs against influenza B and (2) lower seroconversion rates against influenza H1N1. However, among participants with AD with SASC, the response rate is higher among those receiving intramuscular vaccination than those receiving intradermal vaccination.
Most differences were seen in response to influenza B. This result is probably due to a new B strain in the vaccine and low immunogenicity of the B strain. 16, 17 The low immunogenicity of the B strain is an important handicap of inactivated influenza vaccines because recent studies show that the B strain is not less pathogenic than the A strain. 18 The antibody response to influenza vaccines is mainly found within the IgG 1 antibody subclass. 19 Therefore we analyzed IgG 1 , IgG 2 , IgG 3 , and IgA antibody responses to influenza. Our finding that IgG 1 antibody responses after intradermal vaccination were reduced in participants with AD with SASC provided further support for a deficient cutaneous vaccination response in participants with AD with SASC (see Fig E4) .
It is not known whether SASC is simply a biomarker for reduced immune responses to intradermal vaccination or whether S aureus directly inhibits immune responses to intradermal vaccination in participants with AD. We considered the possibility that this association of diminished intradermal vaccine response because of S aureus colonization was related to AD severity. However, when we controlled for the severity of skin disease, SASC remained strongly associated with reduced intradermal vaccine response to influenza vaccination. Previous studies have demonstrated that staphylococcal superantigenic toxins deplete dendritic cells from the skin by inducing migration of cutaneous antigen-presenting cells to the draining lymph nodes. 20 Furthermore, it is known that S aureus products, such as staphylococcal protein A, have subversive effects on B-cell and plasmablast antibody responses. 21 This provides biologic plausibility for the association of S aureus colonization with reduced vaccine antibody responses.
Previous ADRN studies of transcutaneous vaccination to yellow fever virus in skin of patients with AD revealed an inverse association between total serum IgE levels and neutralizing antiviral antibody titers. 22 In the current study of intradermal vaccination, however, reduced anti-influenza antibody responses were independent of baseline serum IgE levels. Our data suggest that the immunologic characteristics of the skin compartment and microbiome might dictate immune responses to influenza vaccines in patients with AD.
Considering that AD is a common health problem, these patients, as well as those with other skin diseases, should be evaluated during early-stage clinical trials that involve cutaneous delivery. New biomarkers, such as total serum IgE and SASC, might prove useful to identify population subsets that might not respond optimally to intradermal vaccination.
A limitation of our current study is that skin swabs for S aureus were not collected on the day of vaccination for 79% of participants. However, microbiologic studies have demonstrated that S aureus colonization can affect more than 90% of patients with severe AD. 23 Persistent S aureus colonization in participants with AD for up to 1 year has been demonstrated in other studies, suggesting that skin swabs obtained at different time points will be relevant to future propensity to S aureus colonization. [24] [25] [26] Another limitation of our study is that because intradermal vaccination is only approved for adults, the current study did not include children. However, it is immunologically plausible that S aureus colonization subverts the skin immune response because eczema herpeticum in all age groups is associated with S aureus colonization. 27 In our current study we conclude that nonatopic participants and participants with AD overall mount similar immune responses to intradermal vaccination. However, the subset of participants with AD with SASC exhibited reduced immune responses after intradermal vaccination compared with participants with AD without SASC. Patients with AD without S aureus colonization had stronger seroprotection and seroconversion against influenza B than nonatopic control subjects (P 5.003 and P 5.01, respectively) and S aureus-colonized patients with AD (P < .001 and P 5 .002, respectively) when they were vaccinated intradermally, suggesting the local environment of the S aureus-colonized skin subverts vaccine immune responses. Because SASC has been reported in the majority of AD, 23 the most prudent approach will be to avoid intradermal influenza vaccination in patients with AD when a suitable vaccine with an alternative route of administration is available and not contraindicated. Clinical implications: Patients with AD colonized with S aureus exhibit reduced immune responses to influenza vaccination compared with noncolonized patients after intradermal but not intramuscular vaccination. Intramuscular influenza vaccination should be given preference in S aureus-colonized patients.
METHODS
Oral and written informed consent were obtained from the study participants. Each participant received a stipend for participating in this protocol.
Ethnicity and race derivation
Ethnicity categories were self-reported from the options of (1) Hispanic or Latino and (2) not Hispanic or Latino. Race categories are reported as follows: (1) black or African American, (2) white, and (3) other. Participants self-reported their own race or races from a list of prespecified case report form race categories, from which general race categories were derived (case report form categories and corresponding derived race categories are defined in Table E1 ). More than 1 self-reported option could be selected. Race was assessed to investigate differences in immune response between groups.
Eligibility criteria
Inclusion criteria included the following: autoimmune disorders, or diabetes at a stage that could interfere with study conduct or completion, based on the opinion of the investigator. Asthma and underlying allergic conditions, such as allergic rhinitis, were not exclusionary. d Had a neoplastic disease or any hematologic malignancy; uncomplicated nonmelanoma skin cancer and melanoma in situ with documentation of complete excision were not exclusionary. Participants who were disease free for at least 6 months were not excluded. Methodology of S aureus culture and laboratory assays S aureus culture. Skin swabs were obtained as part of the ADRN Registry protocol to conduct S aureus cultures. For patients with AD, lesional (most severe lesion) and nonlesional swabs were collected. Nonlesional swabs were collected for nonatopic subjects. The body site priorities for swabbing were the (1) extremities, (2) face/neck, and (3) trunk. Participants had not taken oral antibiotics or topical prescription medications within 7 days before swabbing and had not taken systemic immunosuppressive drugs within 20 days before swabbing. In brief, a skin swab (BD BBL CultureSwab, Liquid Stuart's Transport, and Single Swab) was moistened with nonbacteriostatic saline and used to swab a 5 3 5-cm area. Swabs were then used to inoculate blood agar plates (5% sheep blood; no. R01202; Remel, Lenexa, Kansas).
Plates were incubated up to 48 hours in a 5% CO 2 incubator at 378C. Colonies appearing to be S aureus were tested for coagulase and catalase. If the test results were positive, the colonies were identified as S aureus species. SASC was defined based on S aureus growth in skin cultures. Participants with AD were defined as having SASC if either lesional or nonlesional skin showed S aureus growth.
IgE and IgG antibodies specific for SEB or TSST-1. IgE and IgG antibodies specific for SEB or TSST-1 were measured by using a fluoroenzyme immunoassay (FEIA; ImmunoCAP 250; Thermo Fisher Scientific, Kalamazoo, Mich). The ImmunoCAP is a computer-driven autoanalyzer that uses a solid-phase immunometric (labeled antibody) assay chemistry.
E1-E3
HAI antibody titers. Assays were performed, as previously described, E4 using antigens from the Investigator Reagent Resource, Centers of Disease Control. Sera were incubated at 1:4 in receptor-destroying enzyme solution (Denka Seiken, Tokyo, Japan) for 30 minutes at 568C and subsequently with turkey red blood cells at 48C for 60 minutes to remove nonspecific hemagglutinins. Serial 2-fold dilutions in PBS starting at 1:10 were mixed with 4 HA units of each vaccine virus antigen and turkey red blood cells in 96-well V-bottom microtiter plates (Corning, Corning, NY) for 30 minutes at room temperature. The HAI titer was defined as the reciprocal of the last serum dilution with no HAI activity. A titer of 5 was assigned to samples in which the first dilution was negative. Each run included high-and low-titer positive controls. Assays were considered valid if the control HAI titers had 2-fold or less differences from their previously established mean titers.
Influenza B strain-specific IgG 1 , IgG 2 , IgG 3 , and IgA concentrations. Influenza B strain-specific IgG1, IgG2, and IgG3 J ALLERGY CLIN IMMUNOL VOLUME 139, NUMBER 5 antibody levels were measured by means of capture ELISA with precoated 96-well microtiter plates (M1551; Cell Sciences, Newburyport, Mass). Plates were incubated at 378C for 1.5 hours with the test sera diluted at 1:2 for IgG1, undiluted for IgG2, and diluted 1:4 for IgG3 in the kit-provided diluent. For IgG3 plates, wells were first blocked with 20% FBS for 1 hour and washed before incubating with sera. After washing, 8 HA units of B/Wisconsin/1/2010 in 100 mL of PBS were added to each well and incubated overnight at 48C. Wells were washed the following day, and 100 mL of goat anti-influenza B (AB1058; Millipore, Temecula, Calif) diluted 1:100 in kit diluent were added to each well. After 1 hour at room temperature, wells were washed, and 100 mL of anti-goat-horseradish peroxidase (6300-05; SouthernBiotech, Birmingham, Ala) diluted 1:1000 in diluent were added to each well. After 1 hour at room temperature, wells were washed, and bound antibodies were revealed with ABTS (0401-01; SouthernBiotech). Influenza B strain-specific IgA antibodies were measured by coating 96-well plates with IgA antibody at 2 mg/mL (3860-1AD; Mabtech, Cincinnati, Ohio) overnight. Wells were washed and incubated for 2 hours with test sera diluted 1:20 in diluent. After washing, 8 HA units of B/Florida/4/2006 in 100 ml of PBS was added to each well and incubated at 48C overnight. Wells were washed and 100 mL of antiinfluenza B-horseradish peroxidase (ab20039; Abcam, Cambridge, United Kingdom) were added to each well. After 1 hour at room temperature, wells were washed, and bound antibodies were revealed with ABTS (0401-01; SouthernBiotech). ODs were read with a 405-nm filter on a Multiskan FC instrument (Thermo Fisher). Antibody concentrations were interpolated against the kit-supplied standard curve by using a sigmoidal dose-response variable slope analysis and Prism5 software (GraphPad Software, La Jolla, Calif). 3 and IgA levels by vaccination route, diagnostic group, and S aureus skin colonization. Unadjusted geometric means are displayed for each group. Pairwise comparisons are based on robust regression models of the log 10 value. Values outside the limits of quantification (IgG 3 , 6 and 180 for lower and upper limits, respectively; IgA, 3000 for upper limit) are imputed by using multiple imputation methods and are indicated at the top and bottom of the plots. 10,000 ng/mL 5 1 mg/dL. ID, Intradermal; IM, intramuscular; NA, nonatopic. 
